BioNTech and Pfizer announce approval from Paul-Ehrlich-Institute to commence first clinical trial in Germany for COVID-19 vaccine candidates

BioNTech SE and Pfizer Inc. have announced that the German regulatory authority, the Paul-Ehrlich-Institut, has approved the Phase 1/2 trial for BioNTech’s BNT162 vaccine program to prevent COVID-19 infection. BioNTech and Pfizer are jointly developing BNT162. The trial is the first clinical trial of a COVID-19 vaccine candidate to start in Germany, and is part of a global development program. Pfizer and BioNTech will also conduct trials for BNT162 in the United States upon regulatory approval, which is expected shortly.

For more information, visit the BioNTech website